Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... two transitions; one in leadership, the other in mission. David ... both. Wittwer, who officially succeeded James Barr on New Year's ... from a phone company to a broadband provider. , ... the leadership transition. In part one, he explains the role ...
... - The United States District Court for the Western ... verdict against Abbott Laboratories . , ,The Madison-based court ... company based in Gent, Belgium, and rejected Abbott Labs' request ... Abbott labs for infringing on a genotyping patent. Frank Morich, ...
... In a global economy where good jobs demand innovative ... drill" curriculum and embrace creative learning technologies, such as ... the world of global competition. , ,So argues ... education science professor and author of the new ...
Cached Biology Technology:New CEO at TDS on tech innovation and leadership (Part 1) 2New CEO at TDS on tech innovation and leadership (Part 1) 3New CEO at TDS on tech innovation and leadership (Part 1) 4New book touts educational power of computer games 2New book touts educational power of computer games 3New book touts educational power of computer games 4New book touts educational power of computer games 5
(Date:4/17/2014)... in the Cell Press journal Current Biology ... rather novel sex lives. The Brazilian insects, which represent ... Neotrogla , are the first example of an animal ... been identified in several different animals, Neotrogla ... is also reversed," says Kazunori Yoshizawa from Hokkaido University ...
(Date:4/17/2014)... wild animals and plant life, but there,s an invisible ... in the soil, decomposing organic matter and releasing carbon ... fungi play in ecological systems, their identities have only ... generated a genetic map of more than 10,000 species ... this week in the Proceedings of the National ...
(Date:4/17/2014)... ideas about domestication derive from Charles Darwin, whose ... animal-breeding practices during the 19th century, a period ... , It is from Darwin that we inherit ... animals from wild species and total human control ... management in this industrial setting has been applied ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4
... bacteria that cause acne live on everyone,s skin, yet one ... occasional pimple over a lifetime. In a boon for ... University in St. Louis and the Los Angeles Biomedical Research ... with pimples and "good" strains that may protect the skin. ...
... model suggests that inhospitable hydrodgen-sulphide rich waters could have ... oceans. The research, published online this week in the ... the oceans 550-700 million years ago and shows that ... of complex life, were controlled by the biological availability ...
... studying several hybrid nanomaterials, i.e. combinations of synthetic polymers and ... doctoral thesis at the University of Helsinki in April. ... scale of a billionth of a metre, matter and materials ... it always known what types of effects the nano version ...
Cached Biology News:New study could explain why some people get zits and others don't 2New study could explain why some people get zits and others don't 3Toxic oceans may have delayed spread of complex life 2Is nanosilver toxic? 2Is nanosilver toxic? 3